An FDA-approved injection that works in the brain to increase sexual desire (not blood flow, the way Viagra does).
Low sexual desire — approved for premenopausal women, used more broadly off-label.
Nausea is common (about 40%), the effect is moderate, and it isn't safe for people with heart disease.
What it is
PT-141 is the only peptide in this guide that has gone through the full FDA approval process and come out the other side with an approved prescription. It works in the brain — specifically on pathways that govern sexual desire — rather than in the blood vessels the way Viagra or Cialis do. That difference matters: those medications increase blood flow, which helps with physical response. PT-141 works upstream of that, on desire itself. It was originally developed from a broader compound called Melanotan II, but researchers refined it to be much more selective. Today it's available by prescription as Vyleesi, a self-administered injection taken on demand — not daily.
Potential benefits
HSDD in Premenopausal Women — FDA-Approved Indication
Phase 3 RCTs showed statistically significant improvement in satisfying sexual events and desire scores vs. placebo. Effect size moderate — meaningful for responders. On-demand dosing, not daily.
Sexual Arousal & Desire in Men — Off-Label
Phase 2 data and significant clinical experience support use in men for low desire and PDE5 non-response. Different mechanism means it can work where Viagra/Cialis fail.
Low Libido from Other Causes
Clinical use supports benefit in low libido from hormonal changes, antidepressants, stress, and aging. Formal trial data in these subpopulations limited.
Risks and contraindications
Side Effects (from FDA trials — documented)
- Nausea — ~40% of users; most common adverse event
- Flushing — ~20% of users
- Headache — common
- Injection site reactions
- Transient hyperpigmentation (face, gums, breasts) with repeated use
- Blood pressure elevation — transient; returns to baseline ~12 hours
Serious Risks
- Cardiovascular contraindication: transient BP elevation — explicitly contraindicated in CVD per prescribing information
- Nitrate interaction: serious BP drop risk — absolutely contraindicated
Contraindications / cautions
- Cardiovascular disease · Uncontrolled hypertension — FDA contraindication
- Nitrate medications — absolute contraindication
- Pregnancy · Under 18
Research reality
PT-141 has one of the most complete research records of any peptide in this guide. It went through early safety studies, mid-stage trials, and two large randomized controlled trials — the gold standard for clinical evidence — before receiving FDA approval in 2019. Additional studies have been conducted in men, though that use remains off-label.
Approved by the FDA as Vyleesi for low sexual desire in premenopausal women. Using it for men or postmenopausal women is considered off-label, meaning it goes beyond the formal approval, but that use is supported by clinical experience and earlier trial data.
Because it went through full FDA review, PT-141 has a more complete safety record than any other compound in this guide. The most important things to know: nausea affects roughly 40% of users, and anyone with heart disease or high blood pressure should not use it. Post-market monitoring continues.
The only FDA-approved peptide in this guide. Evidence for its approved use is real and rigorous. A few things to know: the effect size is moderate (it isn't transformative for everyone), nausea is common (~40%), and the cardiovascular contraindication is serious. Heart-health history is the starting point of any conversation about it.